EVAX - Evaxion A/S
4.27
-0.230 -5.386%
Share volume: 31,359
Last Updated: 04-22-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.23%
PREVIOUS CLOSE
CHG
CHG%
$4.50
-0.23
-0.05%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
-4.90%
1 Month
10.05%
3 Months
5.69%
6 Months
-23.89%
1 Year
186.58%
2 Year
3.14%
Key data
Stock price
$4.27
DAY RANGE
$4.27 - $4.53
52 WEEK RANGE
$1.42 - $12.15
52 WEEK CHANGE
$168.55
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-14-2025
NEXT EARNINGS DATE
05-27-2025
Company detail
CEO: Per Norlén
Region: US
Website: evaxion-biotech.com
Employees: 60
IPO year: 2021
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: evaxion-biotech.com
Employees: 60
IPO year: 2021
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Evaxion Biotech A/S identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase 1/2a trial for indications, such as metastatic and unresectable melanoma.
Recent news